Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Food Chem Toxicol ; 133: 110782, 2019 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-31465821

RESUMEN

Cisplatin, carboplatin, and oxaliplatin are some of the most often used alkylating chemotherapeutic agents. In view of the paucity of data on the genotoxicity of oxaliplatin, this study compares the mutagenic activity of cisplatin (0.006, 0.012, 0.025, 0.05 mM), carboplatin (0.1, 0.2, 0,5, 1.0 mM), and oxaliplatin (0.1, 0.2, 0,5, 1.0 mM) using the somatic mutation and recombination test (SMART) in Drosophila melanogaster. Standard and high-bioactivation crosses of the drosophilid were used, which present basal and high levels of cytochrome P450 (CYP450) metabolization enzymes, respectively. All concentrations of cisplatin and carboplatin induced lesions in genetic material in both crosses, while oxaliplatin was mutagenic only to high bioactivation flies treated with 0.1, 0.5 and 1 mM of the compound. No significant differences were observed between genotoxicity values of cisplatin and carboplatin. However, CYP450 enzymes may have affected the mutagenic action of oxaliplatin. Carboplatin induced mainly mutation events, while cisplatin triggered mostly mutation and recombination events when low and high doses were used. Most events induced by oxaliplatin were generated by somatic recombination. Important differences were observed in genotoxic potential of platinum chemotherapeutic compounds, possibly due to the origin and type of the lesions induced in DNA and the repair mechanisms involved.


Asunto(s)
Antineoplásicos/toxicidad , Carboplatino/toxicidad , Cisplatino/toxicidad , Drosophila melanogaster/efectos de los fármacos , Mutágenos/toxicidad , Oxaliplatino/toxicidad , Animales , Daño del ADN/efectos de los fármacos , Drosophila melanogaster/genética , Femenino , Masculino , Mutagénesis/efectos de los fármacos , Pruebas de Mutagenicidad , Mutación/efectos de los fármacos , Recombinación Genética/efectos de los fármacos
2.
Food Chem Toxicol ; 101: 48-54, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-28069374

RESUMEN

The significant contents of artepillin C (AC) in green propolis have prompted research on the biological activities of the compound. The present study evaluated the activity of this phenolic compound on DNA, assessing its genotoxic and antigenotoxic potentials in the somatic mutation and recombination test in Drosophila melanogaster. The standard (ST) and high-bioactivation (HB) crosses were used in the assessment of genotoxic potential, since they express cytochrome P450 metabolization enzymes differently. In the 0.1-1.6 mM concentration range, AC did not have any genotoxic action in either cross. Antigenotoxic potential was investigated using the ST cross. In co- and post-treatment protocols, AC 0.4, 0.8, and 1.6 mM did not modulate mutagenic action of ethyl methanesulphonate. However, though it did not influence the frequency of damage induced by mitomycin C in co-treatment, AC reduced genotoxicity of the mutagen when administered after damage, but only at 0.4 mM. This modulation is associated with the reduction of genetic damage caused by recombinational events. The results of the present study and literature findings indicate that the various responses elicited by AC, namely induction of DNA damage, production of genetic lesions, or activation of DNA repair mechanisms are functions of AC concentration.


Asunto(s)
Daño del ADN/efectos de los fármacos , Drosophila melanogaster/efectos de los fármacos , Fenilpropionatos/toxicidad , Recombinación Genética/genética , Animales , Células Cultivadas , Daño del ADN/genética , Drosophila melanogaster/genética , Pruebas de Mutagenicidad/métodos , Inhibidores de la Síntesis del Ácido Nucleico/toxicidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...